Beaumont, France

Jean-François Haeuw

This inventor holds 18 USPTO granted patents and 9 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Cancer Treatment. Top assignee: Pierre Fabre Medicament. Active years: 2007-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-François Haeuw. Retrieved from https://idiyas.com/inventor/jean-francois-haeuw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 66.7

 

 

Average Co-Inventor Count = 3.6

ph-index = 4

Forward Citations = 84(Granted Patents)


Location History:

  • St Julien en Genevois, FR (2008)
  • Julien en Genevois, FR (2009)
  • St. Julien En Genevois, FR (2012 - 2014)
  • Beaumont, FR (2007 - 2024)

Company Filing History:


Years Active: 2007-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Sulfomaleimide
Immunocytokines
Antibody-Drug Conjugate
IGF-1R
Cancer Treatment
Anti-CD151
Hybrid Receptors
Adjuvant Effect
Anti-JAM-A
Anti-IGF-IR
Therapeutic Composition
Cancer Immunotherapy
18 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jean-François Haeuw

Introduction

Jean-François Haeuw is a prominent inventor based in Beaumont, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel treatments for cancer. With a total of 11 patents to his name, Haeuw's work exemplifies the intersection of innovation and medical science.

Latest Patents

Haeuw's latest patents include groundbreaking inventions such as sulfomaleimide-based linkers and corresponding conjugates. These inventions relate to a linker of a specific formula and its application in linker-drug conjugates, which are crucial for targeted cancer therapies. Additionally, he has developed immunocytokines for the treatment of cancer, which are fusion proteins designed to enhance the efficacy of cancer treatments. These immunocytokines consist of an antibody or antigen-binding fragment fused to a cleavable peptide linker and a cytokine, providing a novel approach to cancer therapy.

Career Highlights

Throughout his career, Jean-François Haeuw has worked with notable companies, including Pierre Fabre Medicament and Pierre Fabre Médicament. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovation and contribute to the development of effective cancer treatments.

Collaborations

Haeuw has collaborated with esteemed colleagues such as Liliane Goetsch and Nathalie Corvaia. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in cancer research.

Conclusion

Jean-François Haeuw's contributions to the field of pharmaceuticals, particularly in cancer treatment, highlight his innovative spirit and dedication to improving patient outcomes. His patents and collaborations reflect a commitment to advancing medical science through inventive solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…